Results 261 to 270 of about 165,216 (289)
Some of the next articles are maybe not open access.
2001
In the 1990’s, many new small and large molecules have been discovered and developed for use as immunosuppressants in transplantation. This chapter focuses on those small molecules that have shown to have immunosuppressive activity in patients1,2 (Fig.1).
Tuija Ikonen +2 more
openaire +2 more sources
In the 1990’s, many new small and large molecules have been discovered and developed for use as immunosuppressants in transplantation. This chapter focuses on those small molecules that have shown to have immunosuppressive activity in patients1,2 (Fig.1).
Tuija Ikonen +2 more
openaire +2 more sources
Neurologic Complications of Immunosuppressive Agents
Neurologic Clinics, 1988The immunosuppressive agents that are an integral part of organ transplantation serve to protect grafts from rejection as well as to prevent or treat GVHD. They include CsA, corticosteroids, OKT3 monoclonal antibody, HDARA-C, azathioprine, and ATG. Of these, all but azathioprine and ATG have direct neurologic complications that are due to the drugs ...
Russell W. Walker, Joel A. Brochstein
openaire +3 more sources
Immunosuppressive Agents on the Horizon
Journal of Pharmacy Practice, 2003The evolution of immunosuppression in organ transplantation has resulted in decreasing rates of rejection and improved allograft survival. The current successes, however, comes at the price of intense drug monitoring, frequent adverse affects, and long-term toxicity.
openaire +2 more sources
The Pharmacokinetics and Pharmacodynamics of Immunosuppressive Agents
Critical Care Nursing Clinics of North America, 1992Designing immunosuppressive regimens for the pediatric transplant patient is challenging because one must balance the need to provide adequate immunosuppression without interfering with normal growth processes or causing long-term adverse consequences.
Kathleen D. Lake +2 more
openaire +3 more sources
Experimental Immunosuppressive Agents
2001Today, many new small and large molecular weight molecules are being developed for use as immunosuppressive agents. As the understanding of mechanisms of immune function improves, immunosuppressive drug discovery and development is able to more specifically target activation pathways that predominate in immune rather than nonimmune cells, thus ...
Jochen Klupp, Randall E. Morris
openaire +2 more sources
Tacrolimus: a new immunosuppressive agent
American Journal of Health-System Pharmacy, 1995The mechanism of action, pharmacokinetics, drug interactions, clinical efficacy, and adverse effects of tacrolimus, a newly approved immunosuppressant drug for use in the prophylaxis of organ rejection after transplantation, are reviewed. Tacrolimus prevents rejection of the transplanted organ by inhibiting the expression of interleukin-2 in T cells ...
Gilbert J. Burckart +2 more
openaire +3 more sources
Use of immunosuppressive agents in uveitis
Current Opinion in Ophthalmology, 2003This review summarizes current patterns in the use of immunosuppressive agents in patients with uveitis.A number of immunosuppressive agents are currently available for the treatment of uveitis. Reports of safety and efficacy, although numerous, have been largely nonrandomized and performed without controls, limiting, to some extent, the strength and ...
Emmett T. Cunningham, Marc Lustig
openaire +3 more sources
The emerging matrix of immunosuppressive agents
Transplantation Proceedings, 2003In recent years, significant milestones have been reached in the field of transplantation through the development of immunosuppressive drugs that inhibit lymphocyte activation, cytokine signal transduction, and cellular proliferation. However, the widespread tissue distribution of the molecular targets exploited to date-calcineurin, mammalian target of
openaire +3 more sources
AEB071 – a promising immunosuppressive agent
Clinical Transplantation, 2009Abstract: In the past decades, allograft survival improved because of the development of new and more specific immunosuppressive agents. The introduction of calcineurin inhibitors was a landmark and acute rejection in organ transplantation decreased remarkably.
Martin Zeier, Claudia Sommerer
openaire +2 more sources
CAM—A NOVEL IMMUNOSUPPRESSIVE AGENT
Transplantation, 1995This is an initial study of the immunosuppressive efficacy of CAM, a derivative of mycophenolic acid, in a rat heart allograft model when the major histocompatibility complex was fully incompatible, and its effect in improving heart allograft survival compared with mycophenolate mofetil (MMF, RS-61443).
Hideo Yagita +5 more
openaire +3 more sources